Read the full paper: Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world setting

Melanie Sturtevant, associate director of policy, evidence and influencing at Breast Cancer Now, said:

The goal of this study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-u...

The goal of this research study is to compare a combination of two drugs, capecitabine and elacestrant to capecitabine alone as a treatment for advanced estrogen receptor-positive (ER+) breast cancer....

Menarini Group presents exciting preliminary data on the efficacy and safety of Elacestrant combined with Capivasertib for ER+/HER2- metastatic breast cancer at ASCO 2026.

Es werden vielversprechende Ergebnisse zur Sicherheit sowie eine vorläufige Wirksamkeitsanalyse der Phase-1b-Behandlung mit Elacestrant und Capivasertib aus der ELEVATE-Studie vorgestellt. Die Wirksamkeitsdaten verdeutlichen, dass die Kombination aus Elacestrant und Capivasertib das...

Menarini Group provides new insights into the ELEVATE study, showcasing the potential of elacestrant and capivasertib for treating ER+, HER2- metastatic breast cancer. Key findings will be showcased at ASCO 2026.

Menarini Group reveals significant data from the ELEVATE clinical study on elacestrant combined with capivasertib for treating ER+, HER2- metastatic breast cancer.

- Menarini Group presenta nuevos datos del estudio de fase 1b/2 ELEVATE de elacestrant en combinación con capivasertib en pacientes con cáncer de mama metastásico (CMm) ER+, HER2- en la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) de 2026 Se presentarán análisis...

Menarini Group has announced promising early results from the ELEVATE study evaluating elacestrant with capivasertib for ER+, HER2- metastatic breast cancer, showcased at ASCO 2026.

Menarini Group has unveiled significant new clinical data concerning advanced cancer treatments at the ASCO Annual Meeting 2026, highlighting innovative therapies.

Menarini Group announces groundbreaking clinical data at the 2026 ASCO Annual Meeting, showcasing advancements in cancer therapies.

Die Daten umfassen sieben Präsentationen zu soliden Tumoren und hämatologischen Malignomen und bieten aktuelle Informationen über den potenziellen Nutzen dieser Therapien für Patienten. Es werden Daten aus der ELEVATE-Studie vorgestellt, die das Potenzial von Elacestrant in Kombination...

Menarini Group shares significant findings on solid tumors and malignancies at ASCO 2026, presenting innovative cancer therapy data.

Les données couvrent sept présentations sur les tumeurs solides et les hémopathies malignes, fournissant des mises à jour sur les avantages potentiels que ces thérapies peuvent apporter aux patients. Les données du schéma elacestrant plus capivasertib de l'étude ELEVATE seront présentées,...

At the upcoming ASCO 2026 meeting, Menarini Group will present new data on groundbreaking cancer therapies impacting both solid tumors and blood malignancies, showcasing their innovative research.

Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. Data from the elacestrant plus capivasertib regimen of the ELEVATE study will be presented underscoring its potential in...

Next-generation selective estrogen receptor-α (ERα) antagonist/degraders (SERDs) are being developed for ER-positive breast cancer (ER+ BC), with intentions of improving outcomes for patients. In recent clinical trials of metastatic ER+ BC, next-generation SERDs demonstrated clinical activity, and elacestrant received an approval for advanced ESR1-mutant disease. However, responses to these drugs were highly heterogeneous: across trials and independent of ESR1 status, 30–50% of patients progressed by their first follow-up scan while other patients sustained benefit for 2 years or more. Here, we interrogate the basis for heterogeneous responses by comparing biopsies from non-responding patients (NR; progression-free survival <2 months) and responding patients (Resp; PFS ≥ 2 months) who received the next-generation SERD giredestrant. While Resp tumors maintain high dependency on ERα signaling, NR tumors exhibit loss of luminal lineage identity and by extension, ERα dependence. NR tumo

La CIPM aprueba la financiación para elacestrant (Orsedu) para el tratamiento de cáncer de mama metastásico con mutación ESR1

Post-CDK4/6 inhibitor therapy HR+ breast cancer is changing with oral SERDs, ESR1 testing, elacestrant, imlunestrant and camizestrant.

## Riepilogo OggettoItalia – Prodotti farmaceutici – FORNITURA, IN SOMMINISTRAZIONE ANNUALE, DEL FARMACO ORSEDU P.A. ELACESTRANT Stazione appaltanteIrccs Fondazione G Pascale TED ID062e8e05-3e7d-4ef3-a1e7-49d958679d71 ### This post is for subscribers only Become a member to get access to all content Subscribe now